HEADER HYDROLASE/HYDROLASE INHIBITOR 16-OCT-95 1CPI
TITLE REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF PEPTIDES. DESIGN
TITLE 2 OF HYDROLYTICALLY STABLE CYCLIC PEPTIDOMIMETIC INHIBITORS OF HIV-1
TITLE 3 PROTEASE
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: HIV-1 PROTEASE;
COMPND 3 CHAIN: A, B;
COMPND 4 SYNONYM: HIV-1 PR;
COMPND 5 ENGINEERED: YES;
COMPND 6 MOL_ID: 2;
COMPND 7 MOLECULE: CYCLIC PEPTIDE INHIBITOR;
COMPND 8 CHAIN: C;
COMPND 9 ENGINEERED: YES
SOURCE MOL_ID: 1;
SOURCE 2 SYNTHETIC: YES;
SOURCE 3 OTHER_DETAILS: CHEMICALLY SYNTHESIZED PROTEIN CORRESPONDING TO THE
SOURCE 4 PROTEASE FROM THE HIV-I;
SOURCE 5 MOL_ID: 2;
SOURCE 6 SYNTHETIC: YES
KEYWDS HYDROLASE-HYDROLASE INHIBITOR COMPLEX
EXPDTA X-RAY DIFFRACTION
AUTHOR J.L.MARTIN
REVDAT 5 05-JUN-24 1CPI 1 REMARK SEQADV LINK
REVDAT 4 13-JUL-11 1CPI 1 VERSN
REVDAT 3 14-JUL-09 1CPI 1 SEQRES HETATM HETNAM
REVDAT 2 24-FEB-09 1CPI 1 VERSN
REVDAT 1 08-MAR-96 1CPI 0
JRNL AUTH G.ABBENANTE,D.R.MARCH,D.A.BERGMAN,P.A.HUNT,B.GARNHAM,
JRNL AUTH 2 R.J.DANCER,J.L.MARTIN,D.P.FAIRLIE
JRNL TITL REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF PEPTIDES
JRNL TITL 2 - DESIGN OF HYDROLYTICALLY-STABLE CYCLIC PEPTIDOMIMETIC
JRNL TITL 3 INHIBITORS OF HIV-1 PROTEASE.
JRNL REF J.AM.CHEM.SOC. V. 117 10220 1995
JRNL REFN ISSN 0002-7863
REMARK 2
REMARK 2 RESOLUTION. 2.05 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : X-PLOR 3.1
REMARK 3 AUTHORS : BRUNGER
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.05
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00
REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000
REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL
REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL
REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.0
REMARK 3 NUMBER OF REFLECTIONS : 11271
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : NULL
REMARK 3 FREE R VALUE TEST SET SELECTION : NULL
REMARK 3 R VALUE (WORKING SET) : 0.163
REMARK 3 FREE R VALUE : 0.237
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.000
REMARK 3 FREE R VALUE TEST SET COUNT : NULL
REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : NULL
REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL
REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL
REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL
REMARK 3 BIN R VALUE (WORKING SET) : NULL
REMARK 3 BIN FREE R VALUE : NULL
REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL
REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL
REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 1541
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 15
REMARK 3 SOLVENT ATOMS : 95
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : NULL
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 20.90
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : NULL
REMARK 3 B22 (A**2) : NULL
REMARK 3 B33 (A**2) : NULL
REMARK 3 B12 (A**2) : NULL
REMARK 3 B13 (A**2) : NULL
REMARK 3 B23 (A**2) : NULL
REMARK 3
REMARK 3 ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.20
REMARK 3 ESD FROM SIGMAA (A) : NULL
REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL
REMARK 3
REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL
REMARK 3 ESD FROM C-V SIGMAA (A) : NULL
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.
REMARK 3 BOND LENGTHS (A) : 0.009
REMARK 3 BOND ANGLES (DEGREES) : 1.590
REMARK 3 DIHEDRAL ANGLES (DEGREES) : 26.90
REMARK 3 IMPROPER ANGLES (DEGREES) : 1.420
REMARK 3
REMARK 3 ISOTROPIC THERMAL MODEL : NULL
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA
REMARK 3 MAIN-CHAIN BOND (A**2) : 1.500 ; NULL
REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.000 ; NULL
REMARK 3 SIDE-CHAIN BOND (A**2) : 2.000 ; NULL
REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.500 ; NULL
REMARK 3
REMARK 3 NCS MODEL : NULL
REMARK 3
REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT
REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL
REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL
REMARK 3
REMARK 3 PARAMETER FILE 1 : NULL
REMARK 3 TOPOLOGY FILE 1 : NULL
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4
REMARK 4 1CPI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL.
REMARK 100 THE DEPOSITION ID IS D_1000172457.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 10-DEC-93
REMARK 200 TEMPERATURE (KELVIN) : 289
REMARK 200 PH : 5.5
REMARK 200 NUMBER OF CRYSTALS USED : NULL
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : N
REMARK 200 RADIATION SOURCE : NULL
REMARK 200 BEAMLINE : NULL
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418
REMARK 200 MONOCHROMATOR : GRAPHITE
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : IMAGE PLATE
REMARK 200 DETECTOR MANUFACTURER : RIGAKU
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : PROCESS (HIGASHI/RIGAKU)
REMARK 200 DATA SCALING SOFTWARE : NULL
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11539
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.050
REMARK 200 RESOLUTION RANGE LOW (A) : 51.000
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 94.0
REMARK 200 DATA REDUNDANCY : 3.000
REMARK 200 R MERGE (I) : 0.07100
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL
REMARK 200 COMPLETENESS FOR SHELL (%) : NULL
REMARK 200 DATA REDUNDANCY IN SHELL : NULL
REMARK 200 R MERGE FOR SHELL (I) : NULL
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: NULL
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL
REMARK 200 SOFTWARE USED: X-PLOR 3.1
REMARK 200 STARTING MODEL: NULL
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 41.94
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.12
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: PH 5.5
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X+1/2,-Y,Z+1/2
REMARK 290 3555 -X,Y+1/2,-Z+1/2
REMARK 290 4555 X+1/2,-Y+1/2,-Z
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.65000
REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000
REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 31.15000
REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.40000
REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 31.15000
REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.65000
REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.40000
REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC
REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC
REMARK 350 SOFTWARE USED: PISA
REMARK 350 TOTAL BURIED SURFACE AREA: 5700 ANGSTROM**2
REMARK 350 SURFACE AREA OF THE COMPLEX: 8990 ANGSTROM**2
REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -56.0 KCAL/MOL
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 400
REMARK 400 COMPOUND
REMARK 400
REMARK 400 THE 1-{(2R)-2-[(8R,11S)-8-(2-AMINO-2-OXOETHYL)-6,9-DIOXO-2-OXA-7,10-
REMARK 400 DIAZABICYCLO[11.2.2]HEPTADECA-1(15),13,16-TRIEN-11-YL]-2-
REMARK 400 HYDROXYETHYL}-L-PROLYL-L-ISOLEUCYL-L-VALINAMIDE IS PEPTIDE-LIKE, A
REMARK 400 MEMBER OF INHIBITOR CLASS.
REMARK 400
REMARK 400 GROUP: 1
REMARK 400 NAME: 1-{(2R)-2-[(8R,11S)-8-(2-AMINO-2-OXOETHYL)-6,9-DIOXO-2-OXA-
REMARK 400 7,10-DIAZABICYCLO[11.2.2]HEPTADECA-1(15),13,16-TRIEN-11-YL]-
REMARK 400 2-HYDROXYETHYL}-L-PROLYL-L-ISOLEUCYL-L-VALINAMIDE
REMARK 400 CHAIN: C
REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER
REMARK 400 DESCRIPTION: NULL
REMARK 470
REMARK 470 MISSING ATOM
REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER;
REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER;
REMARK 470 I=INSERTION CODE):
REMARK 470 M RES CSSEQI ATOMS
REMARK 470 LYS A 41 CG CD CE NZ
REMARK 470 LYS A 43 CG CD CE NZ
REMARK 470 LYS A 45 CG CD CE NZ
REMARK 470 LYS A 70 CG CD CE NZ
REMARK 470 LYS B 41 CG CD CE NZ
REMARK 470 LYS B 43 CG CD CE NZ
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 PRO A 79 85.63 -69.91
REMARK 500 GLU B 35 119.38 -29.36
REMARK 500
REMARK 500 REMARK: NULL
REMARK 800
REMARK 800 SITE
REMARK 800 SITE_IDENTIFIER: AC1
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 502
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC2
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 503
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC3
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 501
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC4
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN C OF CYCLIC PEPTIDE
REMARK 800 INHIBITOR
DBREF 1CPI A 1 99 UNP P03369 POL_HV1A2 57 155
DBREF 1CPI B 1 99 UNP P03369 POL_HV1A2 57 155
DBREF 1CPI C 1 6 PDB 1CPI 1CPI 1 6
SEQADV 1CPI ABA A 67 UNP P03369 CYS 123 CONFLICT
SEQADV 1CPI ABA A 95 UNP P03369 CYS 151 CONFLICT
SEQADV 1CPI ABA B 67 UNP P03369 CYS 123 CONFLICT
SEQADV 1CPI ABA B 95 UNP P03369 CYS 151 CONFLICT
SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE
SEQRES 2 A 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR
SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO
SEQRES 4 A 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY
SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU
SEQRES 6 A 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY
SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR
SEQRES 8 A 99 GLN ILE GLY ABA THR LEU ASN PHE
SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE
SEQRES 2 B 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR
SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO
SEQRES 4 B 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY
SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU
SEQRES 6 B 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY
SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR
SEQRES 8 B 99 GLN ILE GLY ABA THR LEU ASN PHE
SEQRES 1 C 6 ASN RTY PRO ILE VAL NH2
MODRES 1CPI ABA A 67 ALA ALPHA-AMINOBUTYRIC ACID
MODRES 1CPI ABA A 95 ALA ALPHA-AMINOBUTYRIC ACID
MODRES 1CPI ABA B 67 ALA ALPHA-AMINOBUTYRIC ACID
MODRES 1CPI ABA B 95 ALA ALPHA-AMINOBUTYRIC ACID
HET ABA A 67 6
HET ABA A 95 6
HET ABA B 67 6
HET ABA B 95 6
HET RTY C 2 18
HET NH2 C 6 1
HET SO4 A 502 5
HET SO4 A 503 5
HET SO4 B 501 5
HETNAM ABA ALPHA-AMINOBUTYRIC ACID
HETNAM RTY 4-{4-[(2S,3R)-2-AMINO-4-BROMO-3-
HETNAM 2 RTY HYDROXYBUTYL]PHENOXY}BUTANOIC ACID
HETNAM NH2 AMINO GROUP
HETNAM SO4 SULFATE ION
FORMUL 1 ABA 4(C4 H9 N O2)
FORMUL 3 RTY C14 H20 BR N O4
FORMUL 3 NH2 H2 N
FORMUL 4 SO4 3(O4 S 2-)
FORMUL 7 HOH *95(H2 O)
HELIX 1 HA GLY A 86 GLY A 94 1 9
HELIX 2 HB GLY B 86 GLY B 94 1 9
SHEET 1 COA 8 LYS A 43 GLY A 49 0
SHEET 2 COA 8 GLY A 52 ILE A 66 -1
SHEET 3 COA 8 HIS A 69 GLY A 78 -1
SHEET 4 COA 8 THR A 31 GLU A 34 1
SHEET 5 COA 8 ASN A 83 ILE A 85 -1
SHEET 6 COA 8 GLN A 18 ASP A 25 1
SHEET 7 COA 8 PRO A 9 ILE A 15 -1
SHEET 8 COA 8 GLU A 65 ILE A 66 -1
SHEET 1 COB 8 LYS B 43 GLY B 49 0
SHEET 2 COB 8 GLY B 52 ILE B 66 -1
SHEET 3 COB 8 HIS B 69 GLY B 78 -1
SHEET 4 COB 8 THR B 31 GLU B 34 1
SHEET 5 COB 8 ASN B 83 ILE B 85 -1
SHEET 6 COB 8 GLN B 18 ASP B 25 1
SHEET 7 COB 8 PRO B 9 ILE B 15 -1
SHEET 8 COB 8 GLU B 65 ILE B 66 -1
SHEET 1 INT 4 PRO A 1 THR A 4 0
SHEET 2 INT 4 THR B 96 PHE B 99 -1
SHEET 3 INT 4 THR A 96 PHE A 99 -1
SHEET 4 INT 4 PRO B 1 THR B 4 -1
LINK C ILE A 66 N ABA A 67 1555 1555 1.33
LINK C ABA A 67 N GLY A 68 1555 1555 1.33
LINK C GLY A 94 N ABA A 95 1555 1555 1.33
LINK C ABA A 95 N THR A 96 1555 1555 1.34
LINK C ILE B 66 N ABA B 67 1555 1555 1.33
LINK C ABA B 67 N GLY B 68 1555 1555 1.33
LINK C GLY B 94 N ABA B 95 1555 1555 1.33
LINK C ABA B 95 N THR B 96 1555 1555 1.33
LINK N ASN C 1 C2 RTY C 2 1555 1555 1.33
LINK C6 RTY C 2 N PRO C 3 1555 1555 1.47
SITE 1 AC1 2 PRO A 1 HIS A 69
SITE 1 AC2 6 ARG A 14 ARG B 14 ILE B 15 GLY B 16
SITE 2 AC2 6 GLY B 17 HOH B 343
SITE 1 AC3 5 GLY A 68 HIS A 69 LYS A 70 PRO B 1
SITE 2 AC3 5 LYS B 55
SITE 1 AC4 22 ASP A 25 GLY A 27 ALA A 28 ASP A 29
SITE 2 AC4 22 ASP A 30 GLY A 48 GLY A 49 ILE A 50
SITE 3 AC4 22 PRO A 81 HOH A 352 ARG B 8 LEU B 23
SITE 4 AC4 22 ASP B 25 GLY B 27 ALA B 28 ASP B 29
SITE 5 AC4 22 ILE B 47 GLY B 48 GLY B 49 VAL B 82
SITE 6 AC4 22 ILE B 84 HOH C 301
CRYST1 51.300 58.800 62.300 90.00 90.00 90.00 P 21 21 21 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.019493 0.000000 0.000000 0.00000
SCALE2 0.000000 0.017007 0.000000 0.00000
SCALE3 0.000000 0.000000 0.016051 0.00000